Clinical trials: Stage IIB Prostate Cancer AJCC v8
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
RATIONALE: Developing coping strategies may help improve the quality of life of patients with prostate cancer. PURPOSE: This randomized clinical trial is comparing the effect of group therapy with written educational materials on…
- Trial name
- NCT00002848
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 7 sites in United States
- Volunteers
- 480 people
- Sponsor
- Gary Morrow
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Prostate Cancer
Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00967954
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, DNA analysis
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Cancer Research UK
Prostate Cancer, Sexual Dysfunction
High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer
RATIONALE: High-intensity focused ultrasound focal ablation uses high-energy sound waves to kill tumor cells. PURPOSE: This phase II trial is studying the side effects of high-intensity focused ultrasound focal ablation and to…
- Trial name
- NCT00988130
- Testing
- laboratory biomarker analysis, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College London Hospitals
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostate Cancer
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- J-POPS (NCT00534196)
- Testing
- Permanent iodine-125 (Brachytherapy)
- Where
- 31 sites in Japan
- Volunteers
- 6,927 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Nonmalignant Neoplasm, Prostate Cancer
Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia
RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and tomato products, may keep cancer from forming or…
- Trial name
- NCT00416390
- Testing
- lycopene, laboratory biomarker analysis, biopsy
- Volunteers
- 120 people
- Sponsor
- University of Illinois Chicago
Prostate Cancer
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation…
- Trial name
- NCT00003104
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
MRI in Diagnosing Prostate Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help find prostate cancer and learn the extent of disease.
- Trial name
- NCT01292291
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, study of socioeconomic and demographic variables
- Volunteers
- 714 people
- Sponsor
- University College London Hospitals
Osteoporosis, Prostate Cancer
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more…
- Trial name
- NCT00003903
- Testing
- management of therapy complications
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Rochester
Prostate Cancer
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00014586
- Testing
- bicalutamide, goserelin acetate, orchiectomy
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.
- Trial name
- NCT00052481
- Testing
- quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Positron Emission Tomography in Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
- Trial name
- NCT00121212
- Testing
- carbon-11 acetate PET scan
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer
RATIONALE: Learning about changes in DNA over time in patients with prostate cancer undergoing diet and lifestyle changes may help doctors learn about the long-term effects of these changes on disease progression.
- Trial name
- NCT00739791
- Testing
- exercise intervention, gene expression analysis, polymerase chain reaction
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco